467 related articles for article (PubMed ID: 29804474)
1. The utility of the combined use of
Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
Acta Radiol; 2019 Feb; 60(2):230-238. PubMed ID: 29804474
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Parkinson's disease by neuromelanin-sensitive magnetic resonance imaging and
Kuya K; Ogawa T; Shinohara Y; Ishibashi M; Fujii S; Mukuda N; Tanabe Y
Acta Radiol; 2018 May; 59(5):593-598. PubMed ID: 28743197
[TBL] [Abstract][Full Text] [Related]
3. The Utility of the Combined Use of
Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
Yonago Acta Med; 2018 Jun; 61(2):117-127. PubMed ID: 29946218
[TBL] [Abstract][Full Text] [Related]
4. Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism.
Kuya K; Shinohara Y; Miyoshi F; Fujii S; Tanabe Y; Ogawa T
Neuroradiology; 2016 Apr; 58(4):351-6. PubMed ID: 26779912
[TBL] [Abstract][Full Text] [Related]
5. The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.
Uyama N; Otsuka H; Shinya T; Otomi Y; Harada M; Sako W; Izumi Y; Kaji R; Watanabe Y; Takashi S; Kunikane Y
Nucl Med Commun; 2017 Jun; 38(6):487-492. PubMed ID: 28410288
[TBL] [Abstract][Full Text] [Related]
6. Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease?
Okuzumi A; Hatano T; Kamagata K; Hori M; Mori A; Oji Y; Taniguchi D; Daida K; Shimo Y; Yanagisawa N; Nojiri S; Aoki S; Hattori N
Eur J Neurol; 2019 Nov; 26(11):1408-1416. PubMed ID: 31136060
[TBL] [Abstract][Full Text] [Related]
7. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
8. Imaging of the nigrostriatal system for evaluating the preclinical phase of Parkinson's disease development: the utility of neuromelanin, diffusion MRI, and DAT-SPECT.
Takahashi H; Kashiwagi N; Arisawa A; Matsuo C; Kato H; Adachi H; Kajiyama Y; Mochizuki H; Tomiyama N
Br J Radiol; 2022 Feb; 95(1130):20210837. PubMed ID: 34808066
[TBL] [Abstract][Full Text] [Related]
9. The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases.
Sixel-Döring F; Liepe K; Mollenhauer B; Trautmann E; Trenkwalder C
J Neurol; 2011 Dec; 258(12):2147-54. PubMed ID: 21547379
[TBL] [Abstract][Full Text] [Related]
10. Differential diagnosis of parkinsonian syndromes using dopamine transporter and perfusion SPECT.
Takaya S; Sawamoto N; Okada T; Okubo G; Nishida S; Togashi K; Fukuyama H; Takahashi R
Parkinsonism Relat Disord; 2018 Feb; 47():15-21. PubMed ID: 29157745
[TBL] [Abstract][Full Text] [Related]
11. Combined use of dopamine transporter imaging (DAT-SPECT) and
Yoshii F; Ryo M; Baba Y; Koide T; Hashimoto J
J Neurol Sci; 2017 Apr; 375():80-85. PubMed ID: 28320195
[TBL] [Abstract][Full Text] [Related]
12. [123I]FP-CIT SPECT in Clinically Uncertain Parkinsonism Predicts Survival: A Data-Driven Analysis.
Frings L; Henninger F; Treppner M; Köber G; Boeker M; Hellwig S; Buchert R; Meyer PT
J Parkinsons Dis; 2020; 10(4):1457-1465. PubMed ID: 33044193
[TBL] [Abstract][Full Text] [Related]
13. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.
Diaz-Corrales FJ; Sanz-Viedma S; Garcia-Solis D; Escobar-Delgado T; Mir P
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):556-64. PubMed ID: 19862520
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach.
Südmeyer M; Antke C; Zizek T; Beu M; Nikolaus S; Wojtecki L; Schnitzler A; Müller HW
J Nucl Med; 2011 May; 52(5):733-40. PubMed ID: 21498527
[TBL] [Abstract][Full Text] [Related]
16. Utility of Follow-up Dopamine Transporter SPECT With 123I-FP-CIT in the Diagnostic Workup of Patients With Clinically Uncertain Parkinsonian Syndrome.
Apostolova I; Taleb DS; Lipp A; Galazky I; Kupitz D; Lange C; Makowski MR; Brenner W; Amthauer H; Plotkin M; Buchert R
Clin Nucl Med; 2017 Aug; 42(8):589-594. PubMed ID: 28574876
[TBL] [Abstract][Full Text] [Related]
17. Correlations between dopamine transporter density measured by
Maekawa T; Sato N; Ota M; Sugiyama A; Sone D; Enokizono M; Kimura Y; Mukai Y; Murata M; Takano H; Imabayashi E; Matsuda H; Kunimatsu A; Abe O
Jpn J Radiol; 2017 Dec; 35(12):755-759. PubMed ID: 29063467
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
[TBL] [Abstract][Full Text] [Related]
19. Computed-tomography-guided anatomic standardization for quantitative assessment of dopamine transporter SPECT.
Yokoyama K; Imabayashi E; Sumida K; Sone D; Kimura Y; Sato N; Mukai Y; Murata M; Matsuda H
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):366-372. PubMed ID: 27544223
[TBL] [Abstract][Full Text] [Related]
20. Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI.
Shinde S; Prasad S; Saboo Y; Kaushick R; Saini J; Pal PK; Ingalhalikar M
Neuroimage Clin; 2019; 22():101748. PubMed ID: 30870733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
